Browsing Tag
Merus NV
1 post
Genmab’s $8bn takeover of Merus: What it means for biotech M&A and the race to control antibody innovation
Find out how Genmab’s $8B acquisition of Merus and its petosemtamab asset is reshaping the oncology biotech race and investor sentiment today.